Treatment with caspase-1 inhibitor diminishes kidney disease in MRL-<i>Fas^lpr</i> mice and delays systemic illness.

ABSTRACT:

Objectives

To investigate the therapeutic potential of caspase-1 inhibition in systemic lupus erythematosus (SLE) and lupus nephritis (LN) using the MRL-Fas^lpr mouse model.

Methods

Female Murphy Roths large (MRL)-Fas^lpr mice were treated with a caspase-1 inhibitor (pralnacase) or sham treatment from 2.5 to 5.5 months of age. Disease progression was assessed through analysis of systemic and renal parameters, including proteinuria, blood urea nitrogen, kidney histopathology and immune cell infiltration. Cytokine expression and caspase activity were measured to elucidate the mechanism of action. Additional experiments with interleukin (IL)-1 receptor antagonist and pancaspase inhibition treatment as well as post-disease onset intervention wer

SUBMITTER: Claßen P 

PROVIDER: S-EPMC12730834 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature